Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cipla
Cantor Fitzgerald
Baxter
US Department of Justice
Express Scripts
Citi
AstraZeneca
Accenture
Johnson and Johnson

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,174,982

« Back to Dashboard

Summary for Patent: 9,174,982
Title:Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Inventor(s): Bruncko; Milan (Green Oaks, IL), Ding; Hong (Gurnee, IL), Doherty; George A. (Libertyville, IL), Elmore; Steven W. (Northbrook, IL), Hasvold; Lisa A. (Grayslake, IL), Hexamer; Laura (Grayslake, IL), Kunzer; Aaron R. (Schaumburg, IL), Song; Xiaohong (Grayslake, IL), Souers; Andrew J. (Evanston, IL), Sullivan; Gerard M. (Lake Villa, IL), Tao; Zhi-Fu (Gurnee, IL), Wang; Gary T. (Libertyville, IL), Wang; Le (Vernon Hills, IL), Wang; Xilu (Grayslake, IL), Wendt; Michael D. (Vernon Hills, IL), Mantei; Robert A. (Franklin, WI), Hansen; Todd M. (Grayslake, IL)
Assignee: ABBVIE INC. (North Chicago, IL) GENENTECH, INC. (South San Francisco, CA) THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Parkville, AU)
Application Number:14/038,304
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,174,982

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY ➤ Sign Up
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY ➤ Sign Up
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-003 Apr 11, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,174,982

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,546,399 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases ➤ Sign Up
9,045,475 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ➤ Sign Up
8,580,794 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ➤ Sign Up
9,034,875 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,174,982

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
San Marino T201600015 ➤ Sign Up
San Marino T201500225 ➤ Sign Up
Slovenia 2576546 ➤ Sign Up
Slovenia 2435432 ➤ Sign Up
Singapore 10201704742Y ➤ Sign Up
Singapore 185638 ➤ Sign Up
Singapore 175253 ➤ Sign Up
Russian Federation 2628885 ➤ Sign Up
Russian Federation 2015154494 ➤ Sign Up
Russian Federation 2573832 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Accenture
Colorcon
Cerilliant
Express Scripts
Healthtrust
QuintilesIMS
McKesson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot